Maria Dimantas
About Maria Dimantas
Maria Dimantas is the Associate Medical Director of Immuno-Oncology and Hematology at Bristol-Myers Squibb, with over 15 years of experience in the pharmaceutical industry.
Title
Maria Dimantas holds the position of Associate Medical Director, Immuno Oncology and Hematology at Bristol-Myers Squibb. She occupies a significant role in managing and overseeing medical strategies within these specialized domains.
Company
Maria Dimantas is currently employed by Bristol-Myers Squibb, a global biopharmaceutical company widely known for its innovations in immuno-oncology and hematology. She leverages her extensive expertise to contribute to the company's mission of discovering, developing, and delivering innovative medicines.
Previous Positions at AstraZeneca
Before joining Bristol-Myers Squibb, Maria Dimantas held several roles at AstraZeneca. She served as Oncology Group Medical Manager from 2014 to 2015, Group Medical Affairs Manager for Specialty Care in 2014, and Group Medical Affairs Manager for Primary Care TA from 2013 to 2014. Each role allowed her to broaden her expertise in medical management across various care specialties.
Experience at Roche
Maria Dimantas spent six years working at Roche, where she held the positions of Senior Medical Manager, Oncology, from 2010 to 2013, and Medical Consultant from 2007 to 2010. During her tenure, she developed a deep understanding of the oncology field and honed her skills in medical consulting and management.
Education at Universidade Federal de São Paulo
Maria Dimantas completed her education at Universidade Federal de São Paulo (UNIFESP). She studied from 1990 to 1995 and then furthered her education there from 1996 to 1998. Her academic background laid the foundation for her extensive career in the pharmaceutical industry.
Pharmaceutical Industry Experience
Maria Dimantas has accumulated over 15 years of experience in the pharmaceutical industry, focusing predominantly on oncology and specialty care. Her career spans notable companies such as Roche, AstraZeneca, and Bristol-Myers Squibb, highlighting her robust expertise and significant contributions to the field.